Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Buffington Mohr McNeal


Share on StockTwits

Buffington Mohr McNeal trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,980 shares of the medical research company’s stock after selling 138 shares during the period. Thermo Fisher Scientific comprises about 3.1% of Buffington Mohr McNeal’s holdings, making the stock its 7th biggest position. Buffington Mohr McNeal’s holdings in Thermo Fisher Scientific were worth $14,595,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Windward Capital Management Co. CA raised its position in shares of Thermo Fisher Scientific by 1,475.3% during the 4th quarter. Windward Capital Management Co. CA now owns 17,360 shares of the medical research company’s stock worth $8,086,000 after purchasing an additional 16,258 shares during the last quarter. Plimoth Trust Co. LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $687,000. HCR Wealth Advisors grew its stake in Thermo Fisher Scientific by 4.0% in the 4th quarter. HCR Wealth Advisors now owns 7,910 shares of the medical research company’s stock worth $3,684,000 after acquiring an additional 304 shares during the period. Douglass Winthrop Advisors LLC grew its stake in Thermo Fisher Scientific by 9.0% in the 4th quarter. Douglass Winthrop Advisors LLC now owns 13,657 shares of the medical research company’s stock worth $6,361,000 after acquiring an additional 1,122 shares during the period. Finally, Bridge Creek Capital Management LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $203,000. Institutional investors own 87.17% of the company’s stock.

Shares of Thermo Fisher Scientific stock opened at $492.92 on Friday. The firm has a market cap of $193.73 billion, a PE ratio of 40.40, a price-to-earnings-growth ratio of 1.40 and a beta of 0.85. The firm’s 50-day simple moving average is $456.56 and its 200-day simple moving average is $473.32. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.31 and a current ratio of 2.93. Thermo Fisher Scientific Inc. has a 1 year low of $316.36 and a 1 year high of $532.57.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Sunday, January 31st. The medical research company reported $7.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.56 by $0.53. The business had revenue of $10.55 billion for the quarter, compared to analyst estimates of $9.53 billion. Thermo Fisher Scientific had a net margin of 17.12% and a return on equity of 21.35%. The company’s revenue for the quarter was up 54.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.55 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 19.03 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 16th. Investors of record on Tuesday, March 16th were given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.21%. The ex-dividend date was Monday, March 15th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. Thermo Fisher Scientific’s dividend payout ratio is currently 8.42%.

Several analysts have commented on TMO shares. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $488.00 target price for the company. in a research note on Tuesday, December 22nd. Citigroup lifted their target price on shares of Thermo Fisher Scientific from $500.00 to $530.00 and gave the stock a “buy” rating in a research note on Tuesday, February 2nd. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $535.00 to $575.00 and gave the company an “overweight” rating in a research note on Tuesday, February 2nd. KeyCorp raised shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $520.00 price objective for the company in a research note on Wednesday, March 24th. Finally, Credit Suisse Group boosted their price objective on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a research note on Tuesday, January 12th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $525.19.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Story: Capital Gains Distribution

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.